Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U03 Substudy 03C: Zanzalintinib + Belzutifan in Recurrent Clear Cell Renal Cell Carcinoma
NCT07049926Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2025
- Primary completion
- Oct 2031
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 8
01
Overview
A Phase 2 trial of zanzalintinib in renal cell carcinoma (RCC), sponsored by Merck & Co.. Started Jul 2025; status: recruiting.
02
Drugs
zanzalintinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT07049926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07049926.